ReviewTranslational pediatrics2026
Bone marrow kinase X-linked in pulmonary diseases: pathogenic gene, diagnostic biomarker, and treatment target-a narrative review.
Review in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Lung-related diseases impose a substantial global health burden, yet effective diagnostic and therapeutic strategies remain limited. Bone marrow kinase X-linked (BMX), a Tec family non-receptor tyrosine kinase, is increasingly recognized as a critical player in pulmonary pathophysiology. This review aims to systematically evaluate BMX's roles in major lung diseases, clarify its mechanisms, assess its biomarker and therapeutic potential, and identify key knowledge gaps. Methods: We searched PubMed, Web of Science, and Scopus up to December 2025 using keywords related to BMX and pulmonary diseases, with additional references identified from article bibliographies. Key Content and Findings: BMX is implicated in pneumonia, asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and lung cancer via PI3K/AKT, MAPK/ERK, NF‑κB, and TGF‑β/Smad pathways, regulating inflammation, fibrosis, cell survival, and metastasis. BMX expression correlates with disease severity and prognosis, supporting its biomarker potential. Preclinical studies show that BMX inhibitors reduce disease severity in animal models, but clinical translation is hampered by lack of specific biomarkers, limited trials, and challenges in selectivity and resistance. Conclusions: This review synthesizes current knowledge on BMX in pulmonary diseases, highlighting its pathogenic, diagnostic, and therapeutic significance. By outlining current gaps and future directions, it provides a foundation for developing BMX‑targeted precision medicine to ultimately improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.